|
|
Article: GRAZAX(R): Positive 2nd Treatment Year Results Presented at American Conference.(Clinical report)
- Article from:
- PR Newswire Europe
- Article date:
- February 26, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
AAAAI 2007, SAN DIEGO, California, February 26 /PRNewswire/ -- ALK-Abello presents top-line results from the second treatment year in a long-term study with GRAZAX(R). The study shows increased clinical effect and immunological changes in the second treatment year, supporting expectations of a progressive effect with long-term treatment.
Long-term study results for the world's first tablet-based vaccine against grass pollen allergy were presented today at the annual conference of the American Academy of Allergy, Asthma & Immunology (AAAAI 2007) taking place in San Diego. The main results from the second treatment year in the GRAZAX(R) GT-08 study were presented ...